Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma

A randomized phase II selection design study (JCOG0904) was carried out to evaluate the more promising regimen between bortezomib (Bor) plus dexamethasone (Dex; BD) and thalidomide (Thal) plus Dex (TD) in Bor and Thal‐naïve patients with relapsed or refractory multiple myeloma (RRMM). Patients ≥20 a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Sci
Autori principali: Iida, Shinsuke, Wakabayashi, Masashi, Tsukasaki, Kunihiro, Miyamoto, Kenichi, Maruyama, Dai, Yamamoto, Kazuhito, Takatsuka, Yoshifusa, Kusumoto, Shigeru, Kuroda, Junya, Ando, Kiyoshi, Kikukawa, Yoshitaka, Masaki, Yasufumi, Kobayashi, Miki, Hanamura, Ichiro, Asai, Hiroaki, Nagai, Hirokazu, Shimada, Kazuyuki, Tsukamoto, Norifumi, Inoue, Yoshiko, Tobinai, Kensei
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2018
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5980148/
https://ncbi.nlm.nih.gov/pubmed/29478257
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13550
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi